2-hydrazino-3-(3-chlorophenyl)quinazoline-4(3H)-one | 66679-73-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2-hydrazino-3-(3-chlorophenyl)quinazoline-4(3H)-one
• 英文别名: 3-(3-chloro-phenyl)-2-hydrazino-3H-quinazolin-4-one；3-(3-Chlorophenyl)-2-hydrazinylquinazolin-4-one
• CAS: 66679-73-0
• 化学式: C₁₄H₁₁ClN₄O
• 分子量: 286.721
• InChiKey: NHZAKSRENKMJBB-UHFFFAOYSA-N

物化性质

• 熔点：
  222 °C
• 沸点：
  492.1±47.0 °C(Predicted)
• 密度：
  1.46±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  70.7
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-hydrazino-3-(3-chlorophenyl)quinazoline-4(3H)-one 、 丁二酸二乙酯 反应 5.0h， 以32%的产率得到3-[4-(3-Chloro-phenyl)-5-oxo-4,5-dihydro-[1,2,4]triazolo[4,3-a]quinazolin-1-yl]-propionic acid ethyl ester
  参考文献：
  名称：

  Kottke; Kuhmstedt; Knoke, Pharmazie, 1983, vol. 38, # 1, p. 25 - 28

  摘要：

  DOI：
• 作为产物：
  描述：

  3-(3-氯苯基)-2-疏基-3H-喹唑啉-4-酮 在 一水合肼 作用下， 以 乙醇 为溶剂， 以82%的产率得到2-hydrazino-3-(3-chlorophenyl)quinazoline-4(3H)-one
  参考文献：
  名称：

  氰化合溴化物和乙酰乙酸乙酯在杂环中的应用：3-芳基喹唑啉酮四环衍生物的新型合成

  摘要：

  在这项工作中，三环1-氨基-4-（取代的苯基） - [1,2,4]三唑并[4,3一]喹唑啉-5（4 ħ） -酮3用处理2-肼基3的合成-（取代的苯基）喹唑啉-4（3 H）-one 2与溴化氰一起用乙酰乙酸乙酯将其环化，得到目标稠合的喹唑啉-4（3H）one 4稠合四环衍生物。合成的化合物已使用IR和1 H NMR，质谱数据以及元素分析进行了表征。J.杂环化​​学。（2010）。

  DOI：

  10.1002/jhet.440

文献信息

• Synthesis and Anticonvulsant Activity Evaluation of 4-Phenyl-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(4<i>H</i>)-one and Its Derivatives
  作者：Hong-Jian Zhang、Peng Jin、Shi-Ben Wang、Fu-Nan Li、Li-Ping Guan、Zhe-Shan Quan

  DOI：10.1002/ardp.201500115

  日期：2015.8

  A series of 4‐(substituted‐phenyl)‐[1,2,4]triazolo[4,3‐a]quinazolin‐5(4H)‐ones (6a–x) with triazole and other heterocyclic substituents (7–14) were synthesized and the compounds were evaluated for their anticonvulsant activity and neurotoxicity by maximal electroshock (MES) and rotarod neurotoxicity tests. Among the compounds studied, 6o and 6q showed wide margins of safety with protective indices

  一系列具有三唑和其他杂环取代基 (7-14) 的 4-(取代-苯基)-[1,2,4] 三唑并 [4,3-a] 喹唑啉-5(4H)-酮 (6a-x)合成了化合物，并通过最大电休克 (MES) 和旋转棒神经毒性试验评估了化合物的抗惊厥活性和神经毒性。在研究的化合物中，6o 和 6q 显示出广泛的安全范围，其保护指数 (PI) 远高于目前使用的药物（PI6o > 25.5，PI6q > 26.0）。化合物 6o 和 6q 对 MES 诱导的小鼠癫痫发作显示出显着的口服活性，ED50 值分别为 88.02 和 94.6 mg/kg。还发现这两种化合物对由戊四唑和荷包牡丹碱诱发的癫痫发作具有强效活性。
• Identification of potent cholecystokinin-B receptor antagonists: synthesis, molecular modeling and anti-cancer activity against pancreatic cancer cells
  作者：Saroj Kumari、Joyita Chowdhury、Manisha Sikka、Priyanka Verma、Prakash Jha、Anil K. Mishra、Daman Saluja、Madhu Chopra

  DOI：10.1039/c7md00171a

  日期：——

  binding activity (IC50) in the range of 0.2–975 nM and showed good gastric acid secretion inhibitory activity. Molecular modeling of the compounds was done and pharmacophore mapping results showed good prediction of in vitro activity which correlated well with the experimental antagonistic activity. The compounds were further tested for their cytotoxicity on CCK-BR expressing pancreatic cancer cells. The

  胰腺癌晚期恶性程度预后差，几乎没有可用的治疗策略。已知胰腺癌具有独特的与生长相关的受体，该受体在激活后会刺激肿瘤扩散。胃泌素及其相关肽胆囊收缩素（CCK）还通过激活胆囊收缩素-B受体（CCK-BR）显着参与了该癌症类型以及其他恶性肿瘤的生长。有人提出了使用CCK-BR拮抗剂的新治疗策略，以抑制胃泌素的生长促进作用。在本文中，我们报告了结合肼基甲硫代酰胺（化合物3a–g）和肼基（化合物4a–e）的两个喹唑啉酮衍生物的开发）作为开发CCK-BR拮抗剂的接头。使用对接至CCK-BR同源性建模的结构来确定化合物的亲和力。在分离的腔灌注小鼠胃试验中测试了化合物的体外CCK-BR结合和胃酸分泌。这些化合物的CCK-BR结合活性（IC 50）在0.2–975 nM范围内，并具有良好的胃酸分泌抑制活性。对化合物进行了分子建模，药效基因谱分析结果显示了良好的体外预测与实验拮抗活性密切相关的活性。进一步测试化
• Novel Nonpeptide CCK-B Antagonists:  Design and Development of Quinazolinone Derivatives as Potent, Selective, and Orally Active CCK-B Antagonists
  作者：Janak K. Padia、Mark Field、Joanna Hinton、Ken Meecham、Julius Pablo、Rob Pinnock、Bruce D. Roth、Lakhbir Singh、Nirmala Suman-Chauhan、Bharat K. Trivedi、Louise Webdale

  DOI：10.1021/jm970373j

  日期：1998.3.1

  We have designed a novel series of CCK-B receptor antagonists by combining key pharmacophores, an arylurea moiety of 1 and a quinazolinone ring of 3, from two known series. Our earlier studies showed that compounds with methylene linkers in our "target" produced moderate binding affinity and selectivity for CCK-B receptors, whereas its higher and lower homologues resulted in loss of affinity. Introduction of -NH- as a linker dramatically enhanced binding affinity and selectivity for CCK-B receptors, thus providing several compounds with single-digit nanomolar binding affinity and excellent selectivity. Analogous to the earlier studies of the series of quinazolinone derivatives 3, we also found 3-isopropoxyphenyl as a preferred substitution on the N-3 quinazolinone. Electron-withdrawing substitutions on the urea terminal phenyl ring enhanced the CCK-B potency. Representative compounds of this series were tested in the functional assay and showed pure antagonist profiles. Compounds 51 and 61 were orally active in the elevated rat X-maze test. These compounds were also evaluated for their pharmacokinetic profile. The absolute oral bioavailability of compound 61 was 22% in rats.
• KOTTKE K.;KUEHMSTEDT H.;KNOKE D,, PHAMAZIE, 1983, 38, NO 1, 25-28
  作者：KOTTKE K.、KUEHMSTEDT H.、KNOKE D,

  DOI：——

  日期：——
• KOTTKE K.; KUEHMSTEDT H., PHARMAZIE, 1978, 33, NO 1, 19-23
  作者：KOTTKE K.、 KUEHMSTEDT H.

  DOI：——

  日期：——